Funding, launches and regulatory moves across the neurotech startup map.
Subscribed. Check your inbox to confirm.
•
Neurofounders Insights
$ Funding -
Seed
MODALITY
Biomarkers
FORM FACTOR
Software/app
INTERFACE DEPTH
Software
INDICATION
Psychiatry
TARGET USER
Clinicians
REGULATORY STAGE
Investigational
Thymia develops digital biomarkers from speech, video, and gameplay for depression assessment, positioning itself in the multimodal mental-health diagnostics space. Its differentiation is the breadth of behavioral inputs rather than reliance on a single biomarker stream.
Thymia presented an AI model that screens for type 2 diabetes using a 20-second voice recording. It identified 82% of confirmed cases among 801 participants, but produced a 47% false-positive rate. The results have not been peer-reviewed.